Tanaka K and colleagues suggested that reduction in endogenous insulin secretion is an independent risk factor of sarcopenia in men with T2DM.[101] A retrospective observational study reported that insulin treatment significantly increased the 1-year change in SMI compared with noninsulin-treated group. The gene discussed is INS; the disease is sarcopenia.